Uncategorized

Some high-profile tech CEOs have recently elected to take large pay cuts to conserve cash flow. This has sparked a larger conversation about how executive compensation is decided.

Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.

The fall of SVB created a chasm in the life sciences startup sector, locking out funds temporarily and cutting off a source of short-term cash for some startups.

Jounce Therapeutics has received an unsolicited and non-binding acquisition proposal from Concentra Biosciences, looking to buy 100% of Jounce’s equity at a per-share price of $1.80 in cash.

Among the other announcements during the tech giant’s annual healthcare event on Tuesday, Google also shared an a updated version of its medical artificial intelligence that can answer clinical questions at an “expert” level.

The Sweden-based company, which already partnered with Ultra Clean as a distributor, said the deal will “significantly expand” its offerings to sterile reprocessing departments.

Reams of data collected by the National Health Service, paired with advanced work in artificial intelligence at U.K. universities, could make Britain a digital health leader, if the government acts. 

Weeks after the FDA rejected Veru’s Emergency Use Authorization bid for sabizabulin in COVID-19, the company announced plans to continue with late-stage development of the drug.

After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves. 

En 2018, se descubrió que un regulador de la síntesis de proteínas, CPEB4, estaba afectado en la mayoría de los casos de autismo. Los investigadores observaron que los defectos en CPEB4 provocan que la expresión de la mayoría de un conjunto de 200 genes de r …